
==== Front
J Med Case Rep
J Med Case Rep
Journal of Medical Case Reports
1752-1947
BioMed Central London

39218906
4707
10.1186/s13256-024-04707-9
Case Report
Bilateral breast metastases from anaplastic lymphoma kinase-positive lung cancer in a male: a case report
Koh Sumire 1
Koi Yumiko 2
Tajiri Wakako 2
Kawasaki Junji 2
Akiyoshi Sayuri 2
Nakamura Yoshiaki 2
Koga Chinami 2
Okamoto Tatsuro 4
Taguchi Kenichi 3
Tokunaga Eriko tokunaga.eriko.pw@mail.hosp.go.jp

2
1 https://ror.org/020p3h829 grid.271052.3 0000 0004 0374 5913 The Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Kitakyushu, Fukuoka 807-8556 Japan
2 grid.415613.4 Department of Breast Oncology, NHO Kyushu Cancer Center, 3-1-1 Notame, Fukuoka-City, Fukuoka 811-1395 Japan
3 grid.415613.4 Department of Pathology, NHO Kyushu Cancer Center, Fukuoka, Japan. 3-1-1 Notame, Fukuoka-City, Fukuoka 811-1395 Japan
4 grid.415613.4 Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan. 3-1-1 Notame, Fukuoka-City, Fukuoka 811-1395 Japan
2 9 2024
2 9 2024
2024
18 40218 3 2024
18 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Distant metastases from lung cancer are commonly found in the brain, bone, and liver. Metastases to the breast from non-mammary malignancies are extremely rare, and their clinical presentations remain unclear.

Case presentation

We herein report a case of bilateral breast metastases from anaplastic lymphoma kinase-positive advanced lung cancer in a 51-year-old Japanese male patient. During the course of systemic treatment for advanced lung cancer, computed tomography revealed bilateral breast enlargement without contrast enhancement, a finding consistent with gynecomastia. While other metastatic lesions responded to chemotherapy, both breast masses grew vertically like nodules. The breast masses were immunohistochemically diagnosed as metastases from lung cancer and were removed surgically. Simultaneous bilateral breast metastases from malignancies of other organs, like ones in this case, have rarely been described.

Conclusions

It is important to keep in mind that breast metastases from nonmammary malignancies are a possible explanation for unusual breast findings in a patient with a history of malignancies.

Keywords

Lung cancer
Breast metastasis
Anaplastic lymphoma kinase (ALK)
Male
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Breast cancer is one of the most common malignant tumors worldwide [1]. However, metastases to the breast from nonmammary malignancies are scarcely found, accounting for 0.3–2.7% of breast malignancies [2]. Common origins of breast metastases include primary melanomas, lymphomas, and leukemias [3].

Lung cancer is diagnosed as frequently as breast cancer, and its common metastatic sites are the brain, bone, and liver; however, metastases to the breast are rarely found [4–6]. Given the fact that the prevalence of anaplastic lymphoma kinase (ALK) rearrangement is as low as 2–6% of all lung cancer cases, metastases to the breast from ALK-positive lung cancer seem to be highly unusual [7, 8].

Radiologically, the majority of metastases to the breast have been reported to be detected as an incidental finding on imaging in routine practice being scanned for evaluation of treatment response in patients with a history of malignancy [9]. Moreover, previous studies have reported that metastases from nonmammary primaries are more commonly found in the ipsilateral breast than in bilateral breasts and in women than in men [10].

Here we report a case of bilateral breast metastases from ALK-positive lung cancer in a male, which were found during the course of systemic treatment.

Case presentation

A 51-year-old Japanese man with an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 was referred to our department with complaints of gradually progressed bilateral nipple retraction for a year and breast masses with pain for 3 weeks. He was being treated for ALK-positive lung cancer, cT3N3M1b, stage IV since the diagnosis was made at the age of 41 years with no burden of comorbidities. There was no particular past medical or dental history and no oral medication. He had no significant family history of potential future health risks for the patient, including cancer, in the family (second-degree relatives). He was not a smoker and only drinks socially. He works in the hospitality industry. He was initiated on combination chemotherapy with cisplatin (75 mg/m2) and pemetrexed (500 mg/m2) and maintained stable disease for 4 months. During the treatment, he was recruited for the phase 2 clinical trial to assess the efficacy of alectinib (300 mg twice daily) in patients with ALK-positive lung cancer. By administering alectinib, the lung cancer remarkably diminished and he had achieved clinical complete response for almost 3 years. After disease progression with alectinib, the sample from swelling axially lymph node was acquired by lymphadenectomy and confirmed the presence of L1196M mutation in ALK gene using reverse transcription polymerase chain reaction (RT–PCR). The other ALK tyrosine kinase inhibitor (TKI) treatments [ceritinib (750 mg once daily), brigatinib (180 mg once daily), lorlatinib (100 mg once daily)] were sequentially administered over a 9-year period. At 50 years of age, he had been treated with lorlatinib for 3.5 years and computed tomography (CT) performed to evaluate the response to systemic treatment identified bilateral breast enlargement without contrast enhancement, a finding consistent with gynecomastia (Fig. 1A). The patient did not notice any abnormalities with his breasts at that time. These observations initially led physicians to presume that breast enlargement was gynecomastia and did not warrant further examination. At the age of 51, lorlatinib had become no longer effective due to deterioration of pulmonary carcinomatous lymphangiomatosis. He was aware of bilateral nipple retraction but had no concern with it. Following lorlatinib, treatment regimen consisting of atezolizumab (1200 mg), bevacizumab (15 mg/kg), carboplatin (AUC, 5 mg/mL/min), and paclitaxel (175 mg/m2; ABCP) was administered to the patient. A total of 4 months after ABCP therapy was initiated, both breast masses gradually grew in a vertical direction similar to nodules, with contrast enhancement in CT, while other metastatic lesions including pulmonary carcinomatous lymphangiomatosis responded to ABCP therapy (Fig. 1B). Thus, the patient was suspected of having male breast cancer and consulted our department for further evaluation.Fig. 1 Computed tomography (CT) of the patient’s chest. Bilateral breast enlargement without contrast enhancement (A). Growing bilateral breast masses at the time of the consultation (B)

His physical examination revealed a blood pressure of 119/79 mmHg, a heart rate of 92 beats per minute, and oxygen saturation measured by pulse oximetry was 98% on room air. His temperature was 36.5 ℃. Laboratory tests at admission revealed a white blood cell count of 4180/μL, hemoglobin level of 11.0 g/dL, and platelet count of 176,000/μL. Other biochemical tests including liver and renal function showed no significant abnormalities apart from abnormally low albumin levels (3.9 g/dL). The carcinoembryonic antigen level was 3.4 ng/mL and the cytokeratin fragment 19 level was 2.1 ng/mL. There were no signs of inflammation and no findings for infection. Testing for hepatitis B and C infection and human immunodeficiency virus infection showed negative. Urinalysis demonstrated a specific gravity of 1.016, pH 5.5, protein 1+ , and urobilinogen ± . Physical examination revealed hard breast tumors with each nipple retraction, measuring approximately 2 cm × 2 cm at the right side and 2 cm × 1 cm at the left side, respectively, in his bilateral breast (Fig. 2A). Mammography revealed a microlobulated round mass with an unclear boundary in the subareolar area of each breast (Fig. 2B). Ultrasonography showed solid hypoechoic masses that measured about 20 mm and were located below each nipple (Fig. 2C, D).Fig. 2 Breast images of the patient. Gross appearance of the breast (A). Bilateral microlobulated round masses on mammography (B). Hypoechoic irregular-shaped masses in the subareolar area of the right breast (C) and left breast (D) on ultrasound sonography

Pathological analysis of core needle biopsy specimens obtained from the breast masses indicated that the breast lesions were adenocarcinomas with morphological characteristics similar to those observed in the primary lung cancer specimens collected previously from the same patient (Fig. 3A, B). Immunohistochemical examinations revealed positive staining for thyroid transcription factor 1 (TTF-1), ALK, and cytokeratin (CK) 7 and negative staining for mammaglobin, estrogen receptor, gross cystic disease fluid protein 15, and CK20 (Fig. 3C–F). These findings suggested that the breast masses represented metastases from the lung cancer.Fig. 3 Histological findings. Lung adenocarcinoma primary diagnosed from an axillary lymph node biopsy [hematoxylin and eosin (HE), ×20] (A); cancer cells of the left breast (HE, ×20) (B); positive immunohistochemical staining for ALK (×20) (C); positive immunohistochemical staining for TTF-1 (×20) (D), negative immunohistochemical staining for mammaglobin (×20) (E), and negative immunohistochemical staining for estrogen receptor (×20) (F)

He underwent bilateral breast tumorectomy and both tumors were pathologically diagnosed as the metastases from lung cancer as well as core needle biopsy examination. Subsequently, RT–PCR results indicated the presence of G1202R mutation in addition to L1196M in the breast tumor. As no progression lesion was found by removing the bilateral breast tumors, he continued to receive ABCP therapy. After he completed four cycles of ABCP therapy, maintenance therapy with atezolizumab and bevacizumab was continued. As of 8 months after tumorectomy, the patient remained in the stable disease status.

Discussion and conclusions

Here, we presented a case of a male patient with ALK-positive lung cancer in whom bilateral breast masses were initially misinterpreted as gynecomastia, but turned out to be bilateral metastases to the breast. The diagnosis of breast metastases from lung cancer was delayed until almost one year after the first detection of breast masses in CT. This report illustrates the importance of clinical suspicion of breast metastasis when the patient has a clinical history of nonmammary malignancies.

Common presenting symptoms in patients with breast metastases from nonmammary malignancies have been reported to include palpable breast masses, as in those with primary breast cancer [11]. In this case, the retracted nipples were observed before palpable firm masses, due to the presence of a metastatic tumor behind each nipple. When a male patient presents with a unilateral breast mass or bilateral breast masses behind one or both of the nipples, gynecomastia should also be considered as a differential diagnosis [12]. Certain imaging modalities, such as mammography and breast ultrasound, can reveal unusual growth of breast tissue and are useful for differential diagnosis between gynecomastia and breast malignancies [13]. However, the location of bilateral breast enlargement just below the nipples with no contrast enhancement in CT was considered consistent with features of gynecomastia. Imaging findings can also play an important role in suggesting breast tumors; however, they have low specificity in distinguishing primary breast cancer from metastases to the breast [14]. In the present case, metastatic lesions remained stable, except for the growing breast masses; therefore, primary breast cancer, rather than metastasis to the breast, was suspected.

Distinguishing a metastasis to the breast from a primary breast neoplasm is important, since it is of therapeutic and prognostic significance. For accurate differentiation, histological examinations play an important role [15]. In the present study, we performed core needle biopsy of breast masses, and the findings in the hematoxylin and eosin-stained specimens were consistent with those in the lung cancer specimens collected previously from the same patient. Furthermore, immunohistochemical comparison between the primary tumor and metastasis specimens is helpful to confirm a diagnosis [2]. In this case, the immunohistochemical detection of ALK fusion proteins improved diagnostic confidence owing to the detection specificity.

Of note, the patient showed bilateral breast metastases from lung cancer, which are very uncommon. The mechanism of metastatic spread to the breast from lung cancer has been reported to be hematogenous or lymphogenous; however, identifying the route of metastasis is difficult in real clinical practice due to the mechanistic variety and complexity [16]. In elderly individuals, blood flow reduction in breast tissue has been reported due to atrophy of the breast tissue into connective or adipose tissue, resulting in fewer cases of hematogenous metastasis to the breast [17]. Because neither lymphatic nor vascular invasion was seen in the resected specimens, it was difficult to determine the route of bilateral breast metastases from lung cancer in the present case. However, considering the inherently limited volume of breast tissue in male and the initial diagnosis of marked lymph node metastases, even though it is not evident, retrograde lymphatic spread may be a more likely reason for metastases to the breast in this case. Furthermore, harboring ALK-L1196M and -G1202R compound mutations in the breast metastases not only shows high ALK TKIs resistance, but also indicates metastases to the breast can be found in the terminal stage of lung cancer.The prognosis of patients with breast metastases from lung cancer has been reported to be poor [18]. The standard treatment for patients with metastatic lung cancer is systemic therapy, since lung cancer cells can spread around the body from the primary site [19]. Moreover, owing to markedly improved survival in metastatic lung cancer patients treated with modern systemic therapy, the expected survival benefit from surgical treatment of metastatic lesions is considered limited; thus, the decision whether or not to perform surgery should be made on a case-by-case basis [20]. In the current case, the patient received bilateral tumorectomy since breast lesions did not respond well to chemotherapy and only few more chemotherapy options were available. After surgical treatment, the patient continued the same medical treatment as before the surgery, and the postoperative course was uneventful (alive as of 5 months after surgery).

In conclusion, the case highlighted the importance of keeping breast metastasis in mind as a possible explanation for unusual breast findings in a patient with a history of malignancies. Accurate diagnosis of metastatic lesions with biopsies and immunohistochemical examinations is required for tailoring appropriate therapeutic strategies.

Acknowledgements

Not applicable.

Author contributions

OT collected the clinical data. SK and YK wrote the manuscript. WT, JK, SA, YN, CK, and ET acquired and interpreted the patient data. KT performed the pathological examination of the breast tumors. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Informed consent

Informed consent was obtained from the patient included in the study.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Torre LA Islami F Siegel RL Global cancer in women: burden and trends Cancer Epidemiol Biomarkers Prev 2017 26 4 444 457 10.1158/1055-9965.EPI-16-0858 28223433
Torre LA, Islami F, Siegel RL, et al. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev. 2017;26(4):444–57.28223433 10.1158/1055-9965.EPI-16-0858
2. Lee SK Kim WW Kim SH Characteristics of metastasis in the breast from extramammary malignancies J Surg Oncol 2010 101 2 137 140 10.1002/jso.21453 20082359
Lee SK, Kim WW, Kim SH, et al. Characteristics of metastasis in the breast from extramammary malignancies. J Surg Oncol. 2010;101(2):137–40.20082359 10.1002/jso.21453
3. DeLair DF Corben AD Catalano JP Non-mammary metastases to the breast and axilla: a study of 85 cases Mod Pathol 2013 26 3 343 349 10.1038/modpathol.2012.191 23174933
DeLair DF, Corben AD, Catalano JP, et al. Non-mammary metastases to the breast and axilla: a study of 85 cases. Mod Pathol. 2013;26(3):343–9.23174933 10.1038/modpathol.2012.191
4. Siegel RL Miller KD Wagle NS Cancer statistics, 2023 CA Cancer J Clin 2023 73 1 17 48 10.3322/caac.21763 36633525
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.36633525 10.3322/caac.21763
5. Riihimäki M Hemminki A Fallah M Metastatic sites and survival in lung cancer Lung Cancer 2014 86 1 78 84 10.1016/j.lungcan.2014.07.020 25130083
Riihimäki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78–84.25130083 10.1016/j.lungcan.2014.07.020
6. Zhou P Chang N Abraham SC Metastatic nonhematopoietic neoplasms to the breast: a study of 238 cases Hum Pathol 2022 125 59 67 10.1016/j.humpath.2022.04.009 35447141
Zhou P, Chang N, Abraham SC, et al. Metastatic nonhematopoietic neoplasms to the breast: a study of 238 cases. Hum Pathol. 2022;125:59–67.35447141 10.1016/j.humpath.2022.04.009
7. Blackhall FH Peters S Bubendorf L Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project J Clin Oncol 2014 32 25 2780 2787 10.1200/JCO.2013.54.5921 25071109
Blackhall FH, Peters S, Bubendorf L, et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol. 2014;32(25):2780–7.25071109 10.1200/JCO.2013.54.5921
8. Tanimoto A Matsumoto S Takeuchi S Proteasome inhibition overcomes ALK-TKI resistance in ALK-rearranged/TP53-mutant NSCLC via noxa expression Clin Cancer Res 2021 27 5 1410 1420 10.1158/1078-0432.CCR-20-2853 33310890
Tanimoto A, Matsumoto S, Takeuchi S, et al. Proteasome inhibition overcomes ALK-TKI resistance in ALK-rearranged/TP53-mutant NSCLC via noxa expression. Clin Cancer Res. 2021;27(5):1410–20.33310890 10.1158/1078-0432.CCR-20-2853
9. Surov A Fiedler E Holzhausen HJ Metastases to the breast from non-mammary malignancies: primary tumors, prevalence, clinical signs, and radiological features Acad Radiol 2011 18 5 565 574 10.1016/j.acra.2010.12.009 21393030
Surov A, Fiedler E, Holzhausen HJ, et al. Metastases to the breast from non-mammary malignancies: primary tumors, prevalence, clinical signs, and radiological features. Acad Radiol. 2011;18(5):565–74.21393030 10.1016/j.acra.2010.12.009
10. Georgiannos SN Chin J Goode AW Secondary neoplasms of the breast: a survey of the 20th Century Cancer 2001 92 9 2259 2266 10.1002/1097-0142(20011101)92:9<2259::AID-CNCR1571>3.0.CO;2-O 11745279
Georgiannos SN, Chin J, Goode AW, et al. Secondary neoplasms of the breast: a survey of the 20th Century. Cancer. 2001;92(9):2259–66.11745279 10.1002/1097-0142(20011101)92:9<2259::AID-CNCR1571>3.0.CO;2-O
11. Lee AH The histological diagnosis of metastases to the breast from extramammary malignancies J Clin Pathol 2007 60 12 1333 1341 10.1136/jcp.2006.046078 18042689
Lee AH. The histological diagnosis of metastases to the breast from extramammary malignancies. J Clin Pathol. 2007;60(12):1333–41.18042689 10.1136/jcp.2006.046078
12. Kanakis GA Nordkap L Bang AK EAA clinical practice guidelines-gynecomastia evaluation and management Andrology 2019 7 6 778 793 10.1111/andr.12636 31099174
Kanakis GA, Nordkap L, Bang AK, et al. EAA clinical practice guidelines-gynecomastia evaluation and management. Andrology. 2019;7(6):778–93.31099174 10.1111/andr.12636
13. Billa E Kanakis GA Goulis DG Imaging in gynecomastia Andrology 2021 9 5 1444 1456 10.1111/andr.13051 34033252
Billa E, Kanakis GA, Goulis DG. Imaging in gynecomastia. Andrology. 2021;9(5):1444–56.34033252 10.1111/andr.13051
14. Picasso R Pistoia F Zaottini F Breast metastases: updates on epidemiology and radiologic findings Cureus 2020 12 12 e12258 33520480
Picasso R, Pistoia F, Zaottini F, et al. Breast metastases: updates on epidemiology and radiologic findings. Cureus. 2020;12(12): e12258.33520480
15. Fulciniti F Losito S Botti G Metastases to the breast: role of fine needle cytology samples. Our experience with nine cases in 2 years Ann Oncol. 2008 19 4 682 687 10.1093/annonc/mdm546 18048381
Fulciniti F, Losito S, Botti G, et al. Metastases to the breast: role of fine needle cytology samples. Our experience with nine cases in 2 years. Ann Oncol. 2008;19(4):682–7.18048381 10.1093/annonc/mdm546
16. Wang B Jiang Y Li SY Breast metastases from primary lung cancer: a retrospective case series on clinical, ultrasonographic, and immunohistochemical features Transl Lung Cancer Res 2021 10 7 3226 3235 10.21037/tlcr-21-542 34430360
Wang B, Jiang Y, Li SY, et al. Breast metastases from primary lung cancer: a retrospective case series on clinical, ultrasonographic, and immunohistochemical features. Transl Lung Cancer Res. 2021;10(7):3226–35.34430360 10.21037/tlcr-21-542
17. Nielsen M Andersen JA Henriksen FW Metastases to the breast from extramammary carcinomas Acta Pathol Microbiol Scand A 1981 89 4 251 256 7315321
Nielsen M, Andersen JA, Henriksen FW, et al. Metastases to the breast from extramammary carcinomas. Acta Pathol Microbiol Scand A. 1981;89(4):251–6.7315321
18. Williams SA Ehlers RA 2nd Hunt KK Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival Cancer 2007 110 4 731 737 10.1002/cncr.22835 17582626
Williams SA, Ehlers RA 2nd, Hunt KK, et al. Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival. Cancer. 2007;110(4):731–7.17582626 10.1002/cncr.22835
19. Mirrielees JA Kapur JH Szalkucki LM Metastasis of primary lung carcinoma to the breast: a systematic review of the literature J Surg Res 2014 188 2 419 431 10.1016/j.jss.2014.01.024 24560348
Mirrielees JA, Kapur JH, Szalkucki LM, et al. Metastasis of primary lung carcinoma to the breast: a systematic review of the literature. J Surg Res. 2014;188(2):419–31.24560348 10.1016/j.jss.2014.01.024
20. Valenza C Porta FM Rappa A Complex differential diagnosis between primary breast cancer and breast metastasis from EGFR-mutated lung adenocarcinoma: case report and literature review Curr Oncol 2021 28 5 3384 3392 10.3390/curroncol28050292 34590588
Valenza C, Porta FM, Rappa A, et al. Complex differential diagnosis between primary breast cancer and breast metastasis from EGFR-mutated lung adenocarcinoma: case report and literature review. Curr Oncol. 2021;28(5):3384–92.34590588 10.3390/curroncol28050292
